Andrew Hindley1, Zakiyah Zain2, Lisa Wood3, Anne Whitehead4, Alison Sanneh5, David Barber5, Ruth Hornsby5. 1. Rosemere Cancer Centre, Royal Preston Hospital, Preston, United Kingdom. Electronic address: andrew.hindley@lthtr.nhs.uk. 2. College of Arts and Sciences, Universiti Utara Malaysia, Kedah, Malaysia. 3. Department of Social Sciences, Lancaster Medical School, Lancaster, United Kingdom. 4. Medical and Pharmaceutical Statistics Research Unit, Lancaster University, Lancaster, United Kingdom. 5. Rosemere Cancer Centre, Royal Preston Hospital, Preston, United Kingdom.
Abstract
PURPOSE: We wanted to confirm the benefit of mometasone furoate (MF) in preventing acute radiation reactions, as shown in a previous study (Boström et al, Radiother Oncol 2001;59:257-265). METHODS AND MATERIALS: The study was a double-blind comparison of MF with D (Diprobase), administered daily from the start of radiation therapy for 5 weeks in patients receiving breast radiation therapy, 40 Gy in 2.67-Gy fractions daily over 3 weeks. The primary endpoint was mean modified Radiation Therapy Oncology Group (RTOG) score. RESULTS:Mean RTOG scores were significantly less for MF than for D (P=.046). Maximum RTOG and mean erythema scores were significantly less for MF than for D (P=.018 and P=.012, respectively). The Dermatology Life Quality Index (DLQI) score was significantly less for MF than for D at weeks 4 and 5 when corrected for Hospital Anxiety and Depression (HAD) questionnaire scores. CONCLUSIONS:MF cream significantly reduces radiation dermatitis when applied to the breast during and after radiation therapy. For the first time, we have shown a significantly beneficial effect on quality of life using a validated instrument (DLQI), for a topical steroid cream. We believe that application of this cream should be the standard of care where radiation dermatitis is expected. Crown
RCT Entities:
PURPOSE: We wanted to confirm the benefit of mometasone furoate (MF) in preventing acute radiation reactions, as shown in a previous study (Boström et al, Radiother Oncol 2001;59:257-265). METHODS AND MATERIALS: The study was a double-blind comparison of MF with D (Diprobase), administered daily from the start of radiation therapy for 5 weeks in patients receiving breast radiation therapy, 40 Gy in 2.67-Gy fractions daily over 3 weeks. The primary endpoint was mean modified Radiation Therapy Oncology Group (RTOG) score. RESULTS: Mean RTOG scores were significantly less for MF than for D (P=.046). Maximum RTOG and mean erythema scores were significantly less for MF than for D (P=.018 and P=.012, respectively). The Dermatology Life Quality Index (DLQI) score was significantly less for MF than for D at weeks 4 and 5 when corrected for Hospital Anxiety and Depression (HAD) questionnaire scores. CONCLUSIONS:MF cream significantly reduces radiation dermatitis when applied to the breast during and after radiation therapy. For the first time, we have shown a significantly beneficial effect on quality of life using a validated instrument (DLQI), for a topical steroid cream. We believe that application of this cream should be the standard of care where radiation dermatitis is expected. Crown
Authors: Terence T Sio; Pamela J Atherton; Brandon J Birckhead; David J Schwartz; Jeff A Sloan; Drew K Seisler; James A Martenson; Charles L Loprinzi; Patricia C Griffin; Roscoe F Morton; Jon C Anders; Thomas J Stoffel; Robert E Haselow; Rex B Mowat; Michelle A Neben Wittich; James D Bearden; Robert C Miller Journal: Support Care Cancer Date: 2016-04-14 Impact factor: 3.603
Authors: Leonard Christopher Schmeel; David Koch; Frederic Carsten Schmeel; Bettina Bücheler; Christina Leitzen; Birgit Mahlmann; Dorothea Kunze; Martina Heimann; Dilini Brüser; Alina-Valik Abramian; Felix Schoroth; Thomas Müdder; Fred Röhner; Stephan Garbe; Brigitta Gertrud Baumert; Hans Heinz Schild; Timo Martin Wilhelm-Buchstab Journal: Polymers (Basel) Date: 2019-12-16 Impact factor: 4.329